Eli Lilly's Diabetes Pill Shows Significant Advantage Over Competitor
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Source: stocktwits
- Clinical Trial Results: Eli Lilly's experimental diabetes pill, Orforglipron, outperformed oral semaglutide in the large 52-week ACHIEVE-3 trial, demonstrating stronger blood sugar reductions and greater weight loss.
- Trial Scale and Design: The study enrolled 1,698 adults with type 2 diabetes, divided into four treatment groups, including Orforglipron at 12 mg and 36 mg doses, and oral semaglutide at 7 mg and 14 mg doses, ensuring the reliability and broad applicability of the results.
- Significant Clinical Advantages: Orforglipron showed greater reductions in A1C blood sugar levels and body weight compared to oral semaglutide, and it can be taken without food or water timing restrictions, which is crucial for daily diabetes management.
- Positive Market Reaction: Following the announcement, Eli Lilly's shares rose by 0.3% in pre-market trading, reflecting investor optimism regarding Orforglipron's potential market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1126.800
Low
950.00
Averages
1192
High
1500
Current: 1126.800
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Cancer Therapy Significantly Reduces Recurrence Risk
- Clinical Trial Results: Eli Lilly's targeted cancer therapy Retevmo demonstrated an 83% reduction in the risk of recurrence or death in early-stage RET fusion-positive non-small cell lung cancer patients, a significant finding that could influence treatment practices.
- Event-Free Survival Improvement: Among patients with stage II-IIIA disease, the 24-month event-free survival rate was 92% for those treated with selpercatinib, compared to 61% for the placebo group, highlighting the drug's substantial advantage in prolonging survival.
- Global Patient Recruitment: The trial enrolled 151 patients who were randomized to receive either selpercatinib or placebo for up to three years, providing robust evidence for the application of targeted therapies in early lung cancer treatment.
- Safety Profile and Regulatory Plans: While there were adverse events such as elevated liver enzymes, Eli Lilly noted these could be managed through dose adjustments, and plans to submit LIBRETTO-432 data to global regulators for approval in the adjuvant setting.
See More
Micron Technology Surpasses $1 Trillion Market Cap
- Milestone Market Cap: Micron Technology's market capitalization has doubled over the past 48 days to approximately $1.04 trillion, making it one of only 14 companies globally valued at over $1 trillion, reflecting strong performance and market confidence in the semiconductor sector.
- Analyst Target Upgrades: Bank of America nearly doubled its price target for Micron from $500 to $950, while UBS raised its target from $535 to $1,625, indicating strong market confidence in Micron's growth potential, which could drive further stock price increases.
- Strategic Customer Agreement: Micron signed its first long-term supply agreement with a strategic customer for five years, which helps it stand out from the traditional boom-bust cycles of the semiconductor industry, enhancing its market stability and long-term revenue outlook.
- Surge in AI Infrastructure Demand: DRAM and NAND prices are projected to soar by 125% and 234%, respectively, driven by the construction of AI data centers, prompting Micron to undertake a $200 billion expansion plan with multiple high-volume fabs in Idaho and New York to meet the surging market demand.
See More
Wall Street Seeks Broader Market Leadership Amid Stellar Earnings
- Market Fragility Concerns: Despite stellar earnings driving stock indexes to all-time highs, Wall Street is worried about narrow leadership, as Matt Stucky, Chief Portfolio Manager at Northwestern Mutual Wealth Management, noted that such concentration could exacerbate market fragility and impact investor confidence.
- Semiconductor Sector Drive: Micron Technology (MU) crossed the $1 trillion market cap for the first time, becoming the 11th largest public company in the U.S., with its sharp rally contributing 18 points to the S&P 500, highlighting the strong performance of semiconductor and memory-related stocks in propelling the market.
- AI Supercycle: With accelerating demand for AI servers, Dell (DELL) saw its stock soar over 50% last week, while Hewlett Packard (HPE) jumped 12%, indicating that AI-related stocks are leading a new wave of investment interest and attracting more investor attention.
- Future Market Outlook: UBS strategists expect the S&P 500 to rise further in the medium term, targeting 7,900 points, emphasizing that market leadership will broaden beyond megacaps, and recommending diversification into global healthcare, industrials, and infrastructure to navigate market volatility.
See More
Eli Lilly's Retevmo Phase 3 Trial Shows Significant Efficacy
- Clinical Trial Results: Eli Lilly's Retevmo demonstrated significant efficacy in the Phase 3 LIBRETTO-432 trial, achieving a statistically significant 83% reduction in the risk of disease recurrence or death, providing a new treatment option for early-stage RET fusion-positive NSCLC patients.
- Survival Rate Improvement: At a median follow-up of 24 months, the 24-month EFS rate was 92% for the Retevmo group compared to 61% for placebo, indicating Retevmo's potential to improve patient survival rates and possibly change treatment standards.
- Safety Profile: The safety profile of Retevmo was consistent with prior trials, with 17% experiencing elevated ALT and 19% elevated AST, but these adverse events were manageable with dose modifications, indicating good tolerability in clinical settings.
- Market Reaction: Although Eli Lilly's stock price dipped slightly to $1,103.63 following the trial results, the positive clinical data may drive future stock recovery and enhance investor confidence.
See More
LIBRETTO-432 Trial Results Significantly Improve Early Lung Cancer Prognosis
- Clinical Trial Success: Eli Lilly's LIBRETTO-432 trial demonstrates that Retevmo (selpercatinib) as adjuvant therapy significantly improves event-free survival (EFS) in early-stage RET fusion-positive non-small cell lung cancer patients, reducing the risk of recurrence or death by 83%, thus providing a new treatment option for early lung cancer patients.
- Data Publication and Presentation: The trial results will be published in the New England Journal of Medicine and presented at the 2026 ASCO Annual Meeting, highlighting the significance of this research in lung cancer treatment and potentially prompting changes in clinical practice.
- Patient Recruitment and Analysis: A total of 151 patients were enrolled in the trial, randomized to receive either Retevmo or placebo, and after a median follow-up of 24 months, the EFS rate was 94% in the Retevmo group compared to 70% in the placebo group, showcasing the significant efficacy of Retevmo.
- Safety and Tolerability: The safety profile of Retevmo aligns with previous studies, with the most common adverse events being elevated ALT and AST at 17% and 19%, respectively, which can be effectively managed through dose adjustments, ensuring patient safety during treatment.
See More
Stock Market Reaches New Highs on Iran Deal Hopes
- Market Highs: The stock market reached new highs driven by optimistic expectations surrounding the Iran deal, reflecting investor confidence in future economic recovery and potentially attracting more capital inflows.
- Tech Titans Performance: Nvidia and Tesla, among five trillion-dollar companies nearing buy points, indicate strong market interest in tech stocks, which could lead to further price increases in these sectors.
- Improved Investor Sentiment: As market sentiment improves, investors are showing a greater preference for risk assets, which may result in increased capital flowing into high-growth industries, further propelling stock market gains.
- Economic Recovery Outlook: The anticipation of the Iran deal not only boosts short-term stock performance but also lays the groundwork for long-term economic recovery, drawing more investor attention to opportunities in related sectors.
See More
Eli Lilly's Cancer Therapy Significantly Reduces Recurrence Risk
- Clinical Trial Results: Eli Lilly's targeted cancer therapy Retevmo demonstrated an 83% reduction in the risk of recurrence or death in early-stage RET fusion-positive non-small cell lung cancer patients, a significant finding that could influence treatment practices.
- Event-Free Survival Improvement: Among patients with stage II-IIIA disease, the 24-month event-free survival rate was 92% for those treated with selpercatinib, compared to 61% for the placebo group, highlighting the drug's substantial advantage in prolonging survival.
- Global Patient Recruitment: The trial enrolled 151 patients who were randomized to receive either selpercatinib or placebo for up to three years, providing robust evidence for the application of targeted therapies in early lung cancer treatment.
- Safety Profile and Regulatory Plans: While there were adverse events such as elevated liver enzymes, Eli Lilly noted these could be managed through dose adjustments, and plans to submit LIBRETTO-432 data to global regulators for approval in the adjuvant setting.
See More
Micron Technology Surpasses $1 Trillion Market Cap
- Milestone Market Cap: Micron Technology's market capitalization has doubled over the past 48 days to approximately $1.04 trillion, making it one of only 14 companies globally valued at over $1 trillion, reflecting strong performance and market confidence in the semiconductor sector.
- Analyst Target Upgrades: Bank of America nearly doubled its price target for Micron from $500 to $950, while UBS raised its target from $535 to $1,625, indicating strong market confidence in Micron's growth potential, which could drive further stock price increases.
- Strategic Customer Agreement: Micron signed its first long-term supply agreement with a strategic customer for five years, which helps it stand out from the traditional boom-bust cycles of the semiconductor industry, enhancing its market stability and long-term revenue outlook.
- Surge in AI Infrastructure Demand: DRAM and NAND prices are projected to soar by 125% and 234%, respectively, driven by the construction of AI data centers, prompting Micron to undertake a $200 billion expansion plan with multiple high-volume fabs in Idaho and New York to meet the surging market demand.
See More
Wall Street Seeks Broader Market Leadership Amid Stellar Earnings
- Market Fragility Concerns: Despite stellar earnings driving stock indexes to all-time highs, Wall Street is worried about narrow leadership, as Matt Stucky, Chief Portfolio Manager at Northwestern Mutual Wealth Management, noted that such concentration could exacerbate market fragility and impact investor confidence.
- Semiconductor Sector Drive: Micron Technology (MU) crossed the $1 trillion market cap for the first time, becoming the 11th largest public company in the U.S., with its sharp rally contributing 18 points to the S&P 500, highlighting the strong performance of semiconductor and memory-related stocks in propelling the market.
- AI Supercycle: With accelerating demand for AI servers, Dell (DELL) saw its stock soar over 50% last week, while Hewlett Packard (HPE) jumped 12%, indicating that AI-related stocks are leading a new wave of investment interest and attracting more investor attention.
- Future Market Outlook: UBS strategists expect the S&P 500 to rise further in the medium term, targeting 7,900 points, emphasizing that market leadership will broaden beyond megacaps, and recommending diversification into global healthcare, industrials, and infrastructure to navigate market volatility.
See More
Eli Lilly's Retevmo Phase 3 Trial Shows Significant Efficacy
- Clinical Trial Results: Eli Lilly's Retevmo demonstrated significant efficacy in the Phase 3 LIBRETTO-432 trial, achieving a statistically significant 83% reduction in the risk of disease recurrence or death, providing a new treatment option for early-stage RET fusion-positive NSCLC patients.
- Survival Rate Improvement: At a median follow-up of 24 months, the 24-month EFS rate was 92% for the Retevmo group compared to 61% for placebo, indicating Retevmo's potential to improve patient survival rates and possibly change treatment standards.
- Safety Profile: The safety profile of Retevmo was consistent with prior trials, with 17% experiencing elevated ALT and 19% elevated AST, but these adverse events were manageable with dose modifications, indicating good tolerability in clinical settings.
- Market Reaction: Although Eli Lilly's stock price dipped slightly to $1,103.63 following the trial results, the positive clinical data may drive future stock recovery and enhance investor confidence.
See More
LIBRETTO-432 Trial Results Significantly Improve Early Lung Cancer Prognosis
- Clinical Trial Success: Eli Lilly's LIBRETTO-432 trial demonstrates that Retevmo (selpercatinib) as adjuvant therapy significantly improves event-free survival (EFS) in early-stage RET fusion-positive non-small cell lung cancer patients, reducing the risk of recurrence or death by 83%, thus providing a new treatment option for early lung cancer patients.
- Data Publication and Presentation: The trial results will be published in the New England Journal of Medicine and presented at the 2026 ASCO Annual Meeting, highlighting the significance of this research in lung cancer treatment and potentially prompting changes in clinical practice.
- Patient Recruitment and Analysis: A total of 151 patients were enrolled in the trial, randomized to receive either Retevmo or placebo, and after a median follow-up of 24 months, the EFS rate was 94% in the Retevmo group compared to 70% in the placebo group, showcasing the significant efficacy of Retevmo.
- Safety and Tolerability: The safety profile of Retevmo aligns with previous studies, with the most common adverse events being elevated ALT and AST at 17% and 19%, respectively, which can be effectively managed through dose adjustments, ensuring patient safety during treatment.
See More
Stock Market Reaches New Highs on Iran Deal Hopes
- Market Highs: The stock market reached new highs driven by optimistic expectations surrounding the Iran deal, reflecting investor confidence in future economic recovery and potentially attracting more capital inflows.
- Tech Titans Performance: Nvidia and Tesla, among five trillion-dollar companies nearing buy points, indicate strong market interest in tech stocks, which could lead to further price increases in these sectors.
- Improved Investor Sentiment: As market sentiment improves, investors are showing a greater preference for risk assets, which may result in increased capital flowing into high-growth industries, further propelling stock market gains.
- Economic Recovery Outlook: The anticipation of the Iran deal not only boosts short-term stock performance but also lays the groundwork for long-term economic recovery, drawing more investor attention to opportunities in related sectors.
See More
